Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,554 questions in 140 reviews · Heart

current versions

No studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Lidocaine vs placebo or no intervention Adverse events (AEs; adverse drug reaction): asystole · patients with acute myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 2.32 [1.26, 4.26]	4 studies · 6826 participants	Very low
Lidocaine vs aprindine Ventricular fibrillation · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	no estimate extracted	NR	No studies
Lidocaine vs aprindine Coma · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 3 [0.13, 67.06]	1 study · 24 participants	Very low
Lidocaine vs aprindine Seizures · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 5 [0.27, 94.34]	1 study · 24 participants	Very low
Lidocaine vs aprindine Agitation · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 0.2 [0.01, 3.77]	1 study · 24 participants	Very low
Lidocaine vs pirmenol All‐cause mortality · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	no estimate extracted	NR	No studies
Lidocaine vs pirmenol Cardiac mortality · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	no estimate extracted	NR	No studies
Lidocaine vs pirmenol Overall survival at 30 days after myocardial infarction · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	no estimate extracted	NR	No studies
Lidocaine vs pirmenol Ventricular fibrillation · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	no estimate extracted	NR	No studies
Lidocaine vs pirmenol Safety (AEs; adverse drug reaction): any adverse event · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 1.11 [0.47, 2.6]	1 study · 19 participants	Very low
Lidocaine vs placebo or no intervention Adverse events (AEs; adverse drug reaction): sinus bradycardia · patients with acute myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 1.09 [0.66, 1.8]	8 studies · 2549 participants	Very low
Lidocaine vs placebo or no intervention Adverse events (AEs; adverse drug reaction): drowsiness/dizziness · patients with acute myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 3.85 [2.29, 6.47]	6 studies · 2533 participants	Low
Lidocaine vs disopyramide All‐cause mortality · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 1.39 [0.47, 4.13]	2 studies · 144 participants	Very low
Lidocaine vs disopyramide Cardiac mortality · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane	RR 1.02 [0.21, 4.87]	2 studies · 144 participants	Very low
Internet‐based interventions vs usual care or no care Total mortality · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	OR 0.27 [0.04, 1.63]	6 studies · 895 participants	Low
Internet‐based interventions vs usual care or no care Revascularisation · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	OR 0.69 [0.37, 1.27]	6 studies · 895 participants	Low
Internet‐based interventions vs usual care or no care Total cholesterol · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	no estimate extracted	4 studies · 439 participants	Low
Internet‐based interventions vs usual care or no care LDL cholesterol · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	no estimate extracted	4 studies · 437 participants	Low
Internet‐based interventions vs usual care or no care HDL cholesterol · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	no estimate extracted	4 studies · 437 participants	Low
Internet‐based interventions vs usual care or no care Triglycerides · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	no estimate extracted	4 studies · 439 participants	Low
Internet‐based interventions vs usual care or no care Systolic blood pressure · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	no estimate extracted	5 studies · 623 participants	Low
Internet‐based interventions vs usual care or no care Diastolic blood pressure · patients with coronary heart disease Internet‐based interventions for the secondary prevention of coronary heart disease (2015) · Cochrane	no estimate extracted	5 studies · 622 participants	Low
Intervention NR Reversion · People with induced SVT Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia (2015) · Cochrane	no estimate extracted	NR	Low
Intervention NR Reversion · Patients presenting to emergency department with SVT Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia (2015) · Cochrane	no estimate extracted	NR	Low
Fibrates vs control Composite outcome of non‐fatal stroke, non‐fatal myocardial infarction, and vascular death · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.88 [0.83, 0.94]	12 studies · 16064 participants	Moderate
Fibrates vs control Stroke (ischaemic or haemorrhagic, non‐fatal or fatal) during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.94 [0.78, 1.14]	3 studies · 7189 participants	Low
Fibrates vs control Death from any cause during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.98 [0.91, 1.06]	10 studies · 13653 participants	Low
Fibrates vs control Death from vascular causes during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.95 [0.86, 1.05]	10 studies · 13653 participants	Low
Fibrates vs control Myocardial infarction (non‐fatal or fatal) during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.86 [0.8, 0.93]	10 studies · 13942 participants	Moderate
Fibrates vs control Stroke (ischaemic or haemorrhagic, non‐fatal or fatal) during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 1.03 [0.91, 1.16]	6 studies · 11719 participants	Low
Fibrates vs control Composite outcome of non‐fatal stroke, non‐fatal myocardial infarction, and vascular death without clofibrate · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.9 [0.79, 1.03]	7 studies · 10320 participants	Low
Fibrates vs control Death from any cause during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 1.01 [0.91, 1.12]	5 studies · 7909 participants	Low
Fibrates vs control Death from vascular causes during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.98 [0.84, 1.15]	5 studies · 7909 participants	Low
Fibrates vs control Myocardial infarction (non‐fatal or fatal) during the treatment and scheduled · People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke Fibrates for secondary prevention of cardiovascular disease and stroke (2015) · Cochrane	RR 0.85 [0.76, 0.94]	6 studies · 8304 participants	Moderate
Nurse‐led titration vs usual care All‐cause hospital admissions · people with heart failure with reduced ejection fraction Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and… (2015) · Cochrane	RR 0.8 [0.72, 0.88]	4 studies · 560 participants	High
Nurse‐led titration vs usual care Heart failure‐related hospital admissions · people with heart failure with reduced ejection fraction Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and… (2015) · Cochrane	RR 0.51 [0.36, 0.72]	4 studies · 642 participants	Moderate
Nurse‐led titration vs usual care All‐cause mortality · people with heart failure with reduced ejection fraction Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and… (2015) · Cochrane	RR 0.66 [0.48, 0.92]	6 studies · 902 participants	Moderate
Nurse‐led titration vs usual care All‐cause event‐free survival · people with heart failure with reduced ejection fraction Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and… (2015) · Cochrane	RR 0.6 [0.46, 0.77]	3 studies · 370 participants	Moderate
Nurse‐led titration vs usual care Proportion reaching target dose of medications · people with heart failure with reduced ejection fraction Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and… (2015) · Cochrane	RR 1.99 [1.61, 2.47]	5 studies · 966 participants	Low
Intervention NR Occurrence of angiographic restenosis [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.16 [0.07, 0.34]	6 studies · 595 participants	Low
Intervention NR Adverse event · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Occurence of myocardial infarction [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.32 [0.16, 0.66]	13 studies · 1306 participants	Low
Intervention NR Occurrence of angina [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.24 [0.17, 0.34]	11 studies · 1210 participants	Very low
Intervention NR Occurence of heart failure [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.26 [0.11, 0.62]	4 studies · 529 participants	Low
Intervention NR All‐cause mortality [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.38 [0.06, 2.56]	4 studies · 419 participants	Very low
Intervention NR Mortality due to any cardiovascular event [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.31 [0.08, 1.12]	5 studies · 552 participants	Very low
Intervention NR Use of revascularisation [ · participants with CHD after PCI Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention (2015) · Cochrane	RR 0.26 [0.15, 0.45]	8 studies · 806 participants	Low
Intervention NR Cardiovascular event · people with primary prevention of cardiovascular disease in Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and… (2015) · Cochrane	RR 0.57 [0.11, 3.07]	1 study · 232 participants	Low
Intervention NR Systolic blood pressure, change from baseline (mmHg) · people with primary prevention of cardiovascular disease in Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and… (2015) · Cochrane	no estimate extracted	11 studies · 4868 participants	Low
Intervention NR Diastolic blood pressure, change from baseline (mmHg) · people with primary prevention of cardiovascular disease in Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and… (2015) · Cochrane	no estimate extracted	11 studies · 4701 participants	Low